Related Experiment Video
Updated: Aug 16, 2026
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Mutant p53: the loaded gun
1Cancer Center Karolinska (CCK), Karolinska Institute, Stockholm, Sweden. Galina.Selivanova@mtc.ki.se
Abstract:
Alterations in the p53 gene are the most common genetic defects found in tumors so far. Taking into account that p53 is a powerful inducer of cell death it is not surprising that the abolition of its function occurs almost universally during tumor development. There are several features of p53 inactivation in tumors which are quite unique. Firstly, mutations occur at high frequency in the p53 gene, ie, around 50% of human tumors carry p53 mutations. Secondly, mutations are largely of the same type, ie, 87% of them are point missense mutations resulting in a substitution of one amino acid residue. Thirdly, the majority of mutations occur in the DNA binding domain of p53. Finally, mutant p53 proteins accumulate at high levels in tumor cells. Can we take advantage of p53 mutations in tumor cells to selectively kill them? Is this the Achilles heel of tumors that can be exploited for novel non-toxic anticancer therapy? In this review the possible approaches toward reactivation of mutant p53 in tumors will be discussed.
Insights
Mutations in the p53 gene are common in tumors. This review explores strategies to reactivate mutant p53 for targeted cancer therapy, potentially offering a novel, non-toxic treatment approach.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- TP53 gene alterations are the most frequent genetic defects in human tumors.
- p53 protein is a crucial inducer of cell death, and its inactivation is nearly universal in tumor development.
- Mutant p53 proteins accumulate to high levels within tumor cells.
Purpose of the Study:
- To investigate the potential of exploiting p53 mutations for selective tumor cell killing.
- To explore novel, non-toxic anticancer therapeutic strategies targeting p53.
- To review current approaches for reactivating mutant p53 in tumors.
Main Methods:
- Review of existing literature on p53 gene mutations in cancer.
- Analysis of the characteristics of p53 inactivation in tumors.
- Exploration of therapeutic strategies targeting mutant p53.
Main Results:
- Approximately 50% of human tumors harbor p53 mutations.
- 87% of these mutations are missense point mutations within the DNA-binding domain.
- Mutant p53 proteins are overexpressed in tumor cells.
Conclusions:
- The high frequency and specific nature of p53 mutations present a potential therapeutic vulnerability.
- Reactivating mutant p53 could offer a selective and non-toxic approach to cancer treatment.
- Further research into p53 reactivation strategies is warranted for novel anticancer therapies.
Related Concept Videos
01:23Negative Regulator Molecules
02:36DNA Damage can Stall the Cell Cycle
02:23Abnormal Proliferation
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:36DNA Damage Can Stall the Cell Cycle
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...